Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429139 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL8430995 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL27396227 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL27396231 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL4221433 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL6600219 | 1.00 | NOD1 (0.47) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL30844356 | 0.94 | BACE1 (0.46) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL29351532 | 0.93 | NOD1 (0.42) | NOD1ECE1KMT2AALOX15BLM | |
| SCHEMBL16566026 | 0.93 | BACE1 (0.48) | NOD1ECE1FOLH1NAALAD2BMP1 | |
| SCHEMBL29574819 | 0.93 | NOD1 (0.42) | NOD1ECE1KMT2AALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2025-08-21 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-120041530-A | Glutamine peptide with activity of improving alcoholic gastric mucosal injury as well as preparation method and application thereof | 中国食品发酵工业研究院有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-2740790-A1 | COMPOSITION FOR EMBRYO CULTURE | Fuso Pharmaceutical Industries, Ltd. (JP) | 2014-06-11 | — | — | EP | claimed |
| CN-103717730-A | Composition for embryo culture | FUSO PHARMACEUTICAL IND | 2014-04-09 | — | — | CN | claimed |
| CN-103623390-A | Glutamine for use in treating injury | UNIV COLORADO | 2014-03-12 | — | — | CN | claimed |
| EP-1663283-B1 | GLUTAMINE FOR USE IN TREATING INJURY | UNIV COLORADO (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2106791-A1 | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | Biotempt B.V. (NL) | 2009-10-07 | — | — | EP | claimed |
| EP-1663283-A4 | GLUTAMINE FOR USE IN TREATING INJURY | UNIV COLORADO (US) | 2008-08-20 | — | — | EP | claimed |
| CN-1878564-A | Glutamine for the treatment of injury | UNIV COLORADO (US) | 2006-12-13 | — | — | CN | claimed |
| EP-1663283-A1 | GLUTAMINE FOR USE IN TREATING INJURY | University of Colorado (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005034980-A1 | GLUTAMINE FOR USE IN TREATING INJURY | UNIVERSITY OF COLORADO (US) | 2005-04-21 | — | — | WO | claimed |
| US-20050059610-A1 | Glutamine for use in treating injury | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | NOD1 4108/4885ECE1 3928/4885KMT2A 1874/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | NOD1 3625/4885ECE1 4665/4885KMT2A 787/4885 |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | C1S, APOL1, BTN3A1 | NOD1 71/4885ECE1 2728/4885KMT2A 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.